[Effects of magnesium and nicardipine in the cardioplegic solution on the coronary arteries and myocardium].
D000818:Animals; D001826:Body Fluids / Q000378:metabolism; D002121:Calcium Channel Blockers; D003331:Coronary Vessels / Q000187:drug effects*; D004285:Dogs; D006321:Heart / Q000187:drug effects*; D006324:Heart Arrest, Induced; D066298:In Vitro Techniques; D007477:Ions; D008274:Magnesium / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism; D009529:Nicardipine; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010477:Perfusion; D011188:Potassium; D017680:Potassium Compounds; D051381:Rats; D011919:Rats, Inbred Strains; D014665:Vasodilator Agents
D002121:Calcium Channel Blockers; D007477:Ions; D017680:Potassium Compounds; D014665:Vasodilator Agents; C018369:potassium cardioplegic solution; D009529:Nicardipine; D008274:Magnesium; D009543:Nifedipine; D011188:Potassium